Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T13:31:32.492Z.
Calculation as of: 2026-10-06T13:31:32.492Z.
Quote observation: 2026-10-06T13:30:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4936500bc1589ca9a686c77de910b68cd28581e4c5f82a550ef1f7d6df46dce9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Evogene Ltd.
Market Cap
$3.39M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Evogene Ltd. (EVGN) | $3.39M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.37M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.36M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.34M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.93M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.98M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.75M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
